RecruitingNot ApplicableNCT03366051

Sentinel Node Mapping in High Risk Endometrial Cancer

Sentinel Node Mapping Versus Sentinel Node Mapping With Systematic Lymphadenectomy in High Risk Endometrial Cancer: a Open Label, Non-inferiority, Randomized Trial.


Sponsor

AC Camargo Cancer Center

Enrollment

178 participants

Start Date

Dec 22, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants will be randomized in a non-inferiority controlled trial in 2 groups: SLN mapping or SLN mapping followed by systematic lymphadenectomy.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • High grade histologies (endometrioid grade 3, serous, clear cell and carcinosarcoma)
  • Endometrioid grades 1 or 2 with myometrial invasion of ≥50%
  • Endometrioid grades 1 or 2 with cervical invasion
  • Clinically suitable to receive systematic lymphadenectomy
  • Consent statement

Exclusion Criteria3

  • Previous hysterectomy in other institution
  • Presence of extra-uterine disease (peritoneal, visceral or suspicious lymph node metastasis)
  • Previous pelvic node dissection

Interventions

PROCEDURESentinel Node Mapping

At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.

PROCEDURELymphadenectomy

Systematic Pelvic and Para-Aortic Lymphadenectomy


Locations(5)

Hospital Erasto Gaertner

Curitiba, Paraná, Brazil

Hospital do Cancer de Barretos

Barretos, São Paulo, Brazil

AC Camargo Cancer Center

São Paulo, São Paulo, Brazil

Albert Einstein Hospital

São Paulo, São Paulo, Brazil

Sao Camilo Oncologia

São Paulo, São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03366051


Related Trials